What recent returns say about Eli Lilly (LLY)
Eli Lilly (LLY) has seen mixed share performance recently, with a 1.6% decline in the past day, a small gain over the past week, and declines over the past month and past 3 months.
Year to date, the stock shows a 13.0% decline. The 1 year, 3 year, and 5 year total returns remain positive, giving investors a wide range of entry points depending on their time horizon.
See our latest analysis for Eli Lilly.
The recent 13.0% year-to-date share price decline to US$939.47 contrasts with the strong 29.2% one-year and 421.8% five-year total shareholder returns. This suggests that long-term momentum remains intact even as nearer-term enthusiasm has cooled.
If you are curious about what else is moving in healthcare and AI, it could be a good time to scan the market using the 31 healthcare AI stocks
After such strong multi year gains, but a 13.0% year to date pullback and a market value of about US$855b, the key question is simple: is Eli Lilly now undervalued or already pricing in future growth?
Most Popular Narrative: 21% Undervalued
According to the most followed narrative, Eli Lilly’s fair value sits at $1,189.18 against a last close of $939.47, setting up a bullish spread to unpack.
Revenue growth of 20% to 25% per annum for the next 3 to 5 years due to lack of competition in the marketplace. Expecting production capacity to be sorted in the next few years, which will increase units shipped and lower operating costs as time goes on. The 10+ year time frame is still unknown due to new entrants. Confidence in this time frame is low. Based on this forecast and a discount of 9%, using the valuator tool puts the share price at around $1,200 USD.
Want to see what sits behind that rich price tag and discount rate call? The narrative leans heavily on GLP 1 demand, margin strength, and a premium profit multiple that would usually belong to market leaders in faster growing sectors. Curious which exact growth and profitability assumptions line up to justify that $1,189.18 fair value and how they compare to today’s $939.47.
Result: Fair Value of $1,189.18 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upbeat story could be knocked off course if high GLP 1 pricing limits real-world uptake, or if side effect concerns trigger regulatory or legal pushback.
Find out about the key risks to this Eli Lilly narrative.
Another View: What multiples are saying
The popular narrative pegs Eli Lilly at a 21% discount to fair value, but the market’s own yardstick tells a tighter story. At a P/E of 40.7x versus a US pharmaceuticals average of 17x and a peer average of 18.6x, Lilly trades at more than double those benchmarks.
Even against a fair ratio of 39.4x, the current P/E is slightly higher. This points to a slimmer margin of safety than the narrative suggests and tighter room for error if growth or GLP 1 expectations cool. Which signal would you lean on when the story and the sticker price start to disagree?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment pulling in different directions, it helps to see the full picture for yourself, including the mix of risks and rewards that others are focused on, starting with the 4 key rewards and 2 important warning signs.
Looking for more investment ideas?
If you stop at just one company, you risk missing other opportunities that might fit your goals even better, so widen your search before making any big calls.
- Spot potential value opportunities early by scanning the market for 58 high quality undervalued stocks that combine quality fundamentals with more modest pricing.
- Strengthen your focus on resilience by checking out the solid balance sheet and fundamentals stocks screener (41 results) and seeing which names keep financial risk in check.
- Hunt for fresh ideas off the beaten path with the screener containing 23 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com